A global phase III study (NCT04746924) evaluating the superiority of tislelizumab in combination with ociperlimab (an anti-TIGIT antibody) over pembrolizumab in advanced NSCLC patients with PD-L1 expression of ≥50% and a phase III study (NCT04866017) evaluating the superiority of tislelizumab in combination with ociperlimab over durvalumab after chemoradiotherapy are underway, and further developments are anticipated. The gene discussed is CD274; the disease is non-small cell lung carcinoma.